Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study

Andrea Forschner; Florian Battke; Dirk Hadaschik; Martin Schulze; Stephanie Weißgraeber; Tina Han; Maria Kopp; Maximilian Frick; Bernhard Klumpp; Nicola Tietze; Teresa Amaral; Peter Martus; Tobias Sinnberg; Thomas Eigentler; Ulrike Keim; Claus Garbe; Dennis Döcker; Saskia Biskup

doi:10.1186/s40425-019-0659-0

Abstract

High TMB, > 50% decrease of cell-free DNA concentration, and undetectable ctDNA at first follow-up seem to be associated with response and overall survival under combined immunotherapy. The evaluation of ctDNA and cell-free DNA three weeks after treatment initiation may be suitable for early assessment of efficacy of immunotherapy.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Forschner et al. (2019) studied this question.

synapsesocial.com/papers/69deaadf4838c5c0bab0c8fb https://doi.org/10.1186/s40425-019-0659-0

View Full Paper

Ask AI

Bookmark

Share

Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study

Abstract

Discussion

Cite This Study

Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study

Abstract

Discussion

Cite This Study

Keep reading

Keep reading